Tositumomab
From Proteopedia
(Difference between revisions)
| Line 20: | Line 20: | ||
! 167000 | ! 167000 | ||
! 205800 | ! 205800 | ||
| - | ! | + | ! 67000 |
|- | |- | ||
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| Line 32: | Line 32: | ||
! 68 | ! 68 | ||
! 206 | ! 206 | ||
| - | ! | + | ! 108 |
|- | |- | ||
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
| Line 38: | Line 38: | ||
! 32939000 | ! 32939000 | ||
! Rituximab | ! Rituximab | ||
| - | ! | + | ! 17000 |
|- | |- | ||
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ||
Current revision
Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | 67000 |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | 108 |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | 17000 |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
